Risk of Adverse Cardiovascular Outcomes in Differentiated Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis
Pooled result · CV mortalityResult — go to the resultAdjusted relative risk 3.35 CI 1.66–6.67Authors' conclusion
There is limited evidence suggesting that DTC survivors may be at an increased risk of CV death and atrial fibrillation (after adjustment for confounders). We did not observe a significantly increased risk of ischemic heart disease, stroke, or heart failure.
Study context
- Population
- Differentiated thyroid cancer (DTC) survivors compared with the general population; 5 databases searched from inception to October 20217 studies
- Comparison
- DTC survivors vs general population
- Outcome
- CV mortality
Methodological detailsrandom-effects models, adjusted for age and gender, Two reviewers independently screened, extracted and appraised; discrepancies resolved by a third reviewer
- Random-effects models
- Adjusted for age and gender
- Two reviewers independently screened, extracted and appraised; discrepancies resolved by a third reviewer
Pooled result
As reported in the abstract
Adjusted relative risk
3.35
CI 1.66–6.67
DTC survivorsvs General population
aRR 3.35 (CI 1.66–6.67)
Further pooled results
| Outcome | aRR (CI) | |
|---|---|---|
| AF3 studies, 4428 DTC, I2 = 75% | 1.66 (1.22–2.27) | |
| Ischemic heart disease2 studies, 3910 DTC, I2 = 0% | 0.97 (0.84–1.13) | |
| Stroke2 studies, 3910 DTC, I2 = 69% | 1.14 (0.84–1.55) | |
| HF2 studies, 3910 DTC, I2 = 79% | 0.98 (0.60–1.59) | |
| 0.512Adjusted relative risk (log scale) |
Cardiovascular (CV) morbidity, unadjusted data
- CV morbidity risks in unadjusted data similar to adjusted data
Original publication
Risk of Adverse Cardiovascular Outcomes in Differentiated Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis. Thyroid. Published 20 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →